Microbot Medical (NASDAQ: MBOT) and Bio Blast Pharma (NASDAQ:ORPN) are both small-cap bio therapeutic drugs companies, but which is the superior stock? We will contrast the two businesses based on the strength of their valuation, risk, dividends, institutional ownership, analyst recommendations, profitability and earnings.

Valuation and Earnings

This table compares Microbot Medical and Bio Blast Pharma’s top-line revenue, earnings per share (EPS) and valuation.

Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
Microbot Medical $120,000.00 334.53 -$9.66 million ($0.69) -1.51
Bio Blast Pharma N/A N/A -$16.02 million ($2.57) -0.72

Microbot Medical has higher revenue and earnings than Bio Blast Pharma. Microbot Medical is trading at a lower price-to-earnings ratio than Bio Blast Pharma, indicating that it is currently the more affordable of the two stocks.

Risk and Volatility

Microbot Medical has a beta of -0.4, meaning that its share price is 140% less volatile than the S&P 500. Comparatively, Bio Blast Pharma has a beta of -0.05, meaning that its share price is 105% less volatile than the S&P 500.

Profitability

This table compares Microbot Medical and Bio Blast Pharma’s net margins, return on equity and return on assets.

Net Margins Return on Equity Return on Assets
Microbot Medical N/A -157.27% -140.17%
Bio Blast Pharma N/A -144.37% -119.42%

Analyst Recommendations

This is a breakdown of current recommendations and price targets for Microbot Medical and Bio Blast Pharma, as reported by MarketBeat.

Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Microbot Medical 0 0 0 0 N/A
Bio Blast Pharma 0 0 0 0 N/A

Bio Blast Pharma has a consensus price target of $3.15, suggesting a potential upside of 69.35%. Given Bio Blast Pharma’s higher probable upside, analysts plainly believe Bio Blast Pharma is more favorable than Microbot Medical.

Institutional and Insider Ownership

4.7% of Microbot Medical shares are owned by institutional investors. Comparatively, 1.8% of Bio Blast Pharma shares are owned by institutional investors. 31.8% of Microbot Medical shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term.

Summary

Microbot Medical beats Bio Blast Pharma on 5 of the 9 factors compared between the two stocks.

Microbot Medical Company Profile

Microbot Medical Inc., formerly StemCells, Inc., is a medical device company. The Company specializes in the researching, designing, developing and commercializing transformational micro-robotic medical technologies leveraging the artificial and natural lumens within the human body. It is engaged in developing its two product candidates: the Self Cleaning Shunt (SCS) for the treatment of hydrocephalus and normal pressure hydrocephalus (NPH), and TipCAT, a self-propelling, semi-disposable endoscope that the Company is developing for use in colonoscopy procedures. Its ViRob technology is an autonomous crawling micro-robot, which can be controlled remotely or within the body. The Microbot SCS device is a robotic system designed as the ventricular catheter portion of a cerebrospinal fluid (CSF) shunt system. The Company’s TipCAT is an endoscope that provides see and treat capabilities within tubular lumens in the human body, such as the colon, blood vessels and the urinary tract.

Bio Blast Pharma Company Profile

Bioblast Pharma Ltd (BioBlast) is an Israel-based development-stage biopharmaceutical company. The Company is focused on the identification, licensing, acquisition, development and commercialization of drugs for rare and ultra-rare genetic and metabolic diseases. It focuses on therapeutic platforms that offer solutions for several diseases that share a common pathophysiological mechanism, which are the functional changes that accompany a particular syndrome or disease. It also focuses on diseases with severe and debilitating manifestations. The Company has several drug candidates in clinical or preclinical development targeting neuromuscular/central nervous system (CNS) and mitochondrial diseases. Its drug candidates include Trehalose IV Solution, BB-FA (Bioblast-Friedreich’s ataxia) and BBrm-02. The Company’s product candidate platforms include Protein Stabilizing Platform, Read-through Platform and Mitochondrial Protein Replacement Platform.

Receive News & Ratings for Microbot Medical Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Microbot Medical and related companies with MarketBeat.com's FREE daily email newsletter.